EUVIMEDDescoperă EUVIMED
Open access · CC BY 4.0

The everolimus eluting Synergy Megatron TM drug‐eluting stent platform: Early outcomes from the European Synergy Megatron TM Implanters' Registry

Kalpa De Silva, Matthew E Li Kam Wa iD, Tim Wells, Abdul Mozid, Andrew Ladwiniec, Brian G Hynes, Ashish Kotecha, Karim Ratib, Sinjini Biswas iD, Nicolas Amabile, Pierre Deharo, Margaret McEntagart and 6 more

Catheterization and Cardiovascular Interventions · 2023

DOI: 10.1002/ccd.30902 ↗

At a glance

Journal article in Catheterization and Cardiovascular Interventions, 2023. Written by Kalpa De Silva and 17 co-authors. Institution: Cardiovascular Division, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK. Major MEDLINE topics: Drug-Eluting Stents, Coronary Artery Disease, Percutaneous Coronary Intervention, Thrombosis. Cited 4 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY 4.0). Funded by: British Heart Foundation.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

The Synergy Megatron TM is an everolimus‐drug eluting stent that may offer advantages in the treatment of aorto‐ostial disease and large proximal vessels.

Aims

To report the short‐ to medium‐term clinical outcomes from the European Synergy Megatron TM Implanters' Registry.

Methods

This registry was an investigator‐initiated study conducted at 14 European centers. The primary outcome was target lesion failure (TLF), defined as the composite of cardiovascular death, target vessel myocardial infarction (MI), and target lesion revascularisation.

Results

Five hundred seventy‐five patients underwent PCI with Megatron TM between 2019 and 2021. Patients were 69 ± 12 years old, 26% had diabetes mellitus, 24% had moderate‐severe left ventricular impairment and 59% presented with an acute coronary syndrome. 15% were deemed prohibitively high risk for surgical revascularisation. The target vessel involved the left main stem in 55%, the ostium of the RCA in 13% and was a true bifurcation (Medina 1,1,1) in 50%. At 1 year, TLF was observed in 40 patients, with 26 (65%) occurring within the first 30 days. The cumulative incidence of TLF was 4.5% at 30 days and 8.6% (95% CI 6.3–11.7) at 1 year. The incidence of stent thrombosis was 0.5% with no late stent thromboses. By multivariate analysis, the strongest independent predictors of TLF were severe left ventricular impairment (HR 3.43, 95% CI: 1.67–6.76, p < 0.001) and a target vessel involving the left main (HR 4.00 95% CI 1.81–10.15 p = 0.001).

Conclusions

Use of the Synergy Megatron TM everolimus eluting stent in a ‘real‐world’ setting shows favorable outcomes at 30 days and 1 year.

Subjects

MeSH terms (MEDLINE)

Drug-Eluting StentsCoronary Artery DiseasePercutaneous Coronary InterventionThrombosisHumansMiddle AgedAgedAged, 80 and overEverolimusTreatment OutcomeRisk FactorsRegistries

Author keywords

bifurcationdrug-eluting stentleft main

Substances

Everolimus

Authors and institutions

  • Cardiovascular Division, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Coronary Research Group, British Heart Foundation Centre of Research Excellence, King's College London, London, UK.
  • Cardiology Department, Salisbury District Hospital, Salisbury NHS Foundation Trust, Salisbury, UK.
  • Cardio Respiratory Clinical Services Unit, Leeds General Infirmary, The Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Department of Cardiology, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Cardiology Department, University Hospital Galway, Galway, Ireland.

ORCID profiles: Matthew E Li Kam Wa, Sinjini Biswas, James C Spratt, Jonathan A Mailey

Funding

  • British Heart Foundation

Cite

APA

De Silva, K., Li Kam Wa, M. E., Wells, T., Mozid, A., Ladwiniec, A., Hynes, B. G., Kotecha, A., Ratib, K., Biswas, S., Amabile, N., Deharo, P., McEntagart, M., Spratt, J. C., Digne, F., Hogg, M., Mailey, J. A., Walsh, S. J., & Kalra, S. S. (2023). The everolimus eluting Synergy Megatron TM drug‐eluting stent platform: Early outcomes from the European Synergy Megatron TM Implanters' Registry. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30902

Vancouver

De Silva K, Li Kam Wa ME, Wells T, Mozid A, Ladwiniec A, Hynes BG, et al. The everolimus eluting Synergy Megatron TM drug‐eluting stent platform: Early outcomes from the European Synergy Megatron TM Implanters' Registry. Catheterization and Cardiovascular Interventions. 2023. doi:10.1002/ccd.30902

BibTeX
@article{DeSilva2023,
  author = {De Silva, Kalpa and Li Kam Wa, Matthew E and Wells, Tim and Mozid, Abdul and Ladwiniec, Andrew and Hynes, Brian G and Kotecha, Ashish and Ratib, Karim and Biswas, Sinjini and Amabile, Nicolas and Deharo, Pierre and McEntagart, Margaret and Spratt, James C and Digne, Franck and Hogg, Meadhbh and Mailey, Jonathan A and Walsh, Simon J and Kalra, Sundeep S},
  title = {The everolimus eluting Synergy Megatron TM drug‐eluting stent platform: Early outcomes from the European Synergy Megatron TM Implanters' Registry},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2023},
  doi = {10.1002/ccd.30902}
}
Start for free →